Emerging treatments

Early corticosteroid administration

An open-label randomized controlled study of patients with moderate-to-severe ARDS found that early dexamethasone resulted in a substantial increase in ventilator-free days (4.8 days), and a 15% reduction in mortality, compared with placebo.[128] These findings need to be validated and must be considered cautiously given serious concerns about the safety of glucocorticoids in critically ill patients who do not have COVID-19.

Use of this content is subject to our disclaimer